Patrick J. Heron, Director at Arcutis Biotherapeutics, Inc. (ARQT), bought 2,268 shares at $13.41 ($30K) on 2025-06-05, disclosed to the SEC on 2025-06-06.
Seasonal purchase ($30k) by Director — this insider has traded ARQT in June in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.32 | 1,890 | $25K | 83.2% |
| 2 | $13.41 | 378 | $5K | 16.8% |
| Total | $13.33 avg | 2,268 | $30K | 100% |
| Filing → |
| ARQT | BUY | 2025-05-23 | $69K | — | Filing → |
| ARQT | BUY | 2025-05-19 | $34K | — | Filing → |
| ARQT | BUY | 2025-05-15 | $119K | — | Filing → |